Farmak ranked 9th in the “25 Most Valuable Brands in Ukraine” list, compiled by Forbes Ukraine. The pharmaceutical company’s brand value was estimated at $69 million.
This marks the first time Forbes Ukraine has assessed the value of leading Ukrainian brands. The ranking features 25 brands from various economic sectors, with a combined value of nearly $2 billion.
To calculate brand value, Forbes employed a methodology used by investment analysts. From a list of Ukraine’s 202 largest companies, the selection was narrowed down to non-financial businesses with B2C brands and annual sales of at least $50 million in 2025 (or $200 million for retail chains). The market value of each business was estimated based on benchmarks from comparable publicly traded companies globally, as of the first half of October 2026. Subsequently, industry-specific coefficients were applied to determine the brand’s share of the total business value.
The history of Farmak began in 1925 in Kyiv with the M. Lomonosov Synthetic Drug Plant. Over the course of a century, the company has evolved from a local manufacturer into an international pharmaceutical group. Today, the Farmak Group operates production facilities in Ukraine and Spain, exports medicines to over 60 countries, and maintains its own research and development infrastructure. The company’s portfolio comprises more than 450 medicinal products, and its annual investment in drug research and development exceeds $15 million. Other participants in the ranking include Roshen, Kyivstar, Nova Poshta, Morshynska, Aurora, and others.
